Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

MyoKardia

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020. MyoKardia is a clinical-stage biopharmaceutical company discove

Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash

Costco

NextEra Energy

Philip Morris

AT&T

You'll sleep easy if you own these time-tested and highly profitable businesses.

5 Safe Stocks to Buy if the Stock Market Crashes

It's not the first time Opdivo and Yervoy have gotten the nod to treat a form of cancer.

Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients

Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--FDA Approves Opdivo + Yervoy as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

Cerner

Colgate-Palmolive

Dollar General

General Mills

Hormel Foods

Johnson & Johnson

Kellogg

Kimberly-Clark

Republic Services

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

The stock market suffered a turbulent September, and a number of factors are pointing toward an equally bumpy rest of the year. That likely will have investors looking for a smoother market ride than what the major indices have to offer – and one such way to do that is to buy low-volatility stocks to manage risk.

12 Low-Volatility Stocks to Stabilize Your Portfolio

WASHINGTON & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #UNCF--UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026

UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026

NEW YORK--(BUSINESS WIRE)---- $BMY--BMS to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia® (ozanimod) in Ulcerative Colitis at UEG Week

 Bristol Myers Squibb to Host Virtual Investor Event to Discuss Results from Phase 3 True North Trial Evaluating Zeposia® (ozanimod) in Ulcerative Colitis at UEG Week 2020

In trading on Tuesday, shares of Bristol-Myers Squibb crossed above their 200 day moving average of $60.58, changing hands as high as $60.94 per share.

Bristol-Myers Squibb Crosses Above Key Moving Average Level

ABM Industries

Accenture Plc

Acme United

Automatic Data Processing

Albemarle

Allstate

Andersons

Air Products and Chemicals

Alexandria Real Estate Equities

Artesian Resources

Atrion

Broadcom

Axis Capital

BancFirst

Becton, Dickinson and Co.

Franklin Resources

Brookfield Renewable Partners

Brookfield Infrastructure Partners L.P.

Broadridge Financial

Cardinal Health

C.H. Robinson Worldwide

Comerica

Canadian National Railway Company

American Tower

A weekly summary of dividend activity for Dividend Champions and Contenders.

Dividend Champion And Contender Highlights: Week Of September 27

Bristol-Myers' (BMY) Opdivo meets primary endpoint in a phase III study in patients with urothelial carcinoma.

Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study

Con Ed

McDonald's

PepsiCo

September is doing what September often does, and the Robinhood traders who are long out of the money call options, and stocks they bought on margin are getting clipped pretty well.

BofA Securities Has 5 Safe High-Dividend Stocks for Worried Investors to Buy Now

Stick with Bristol-Myers Squibb stock which is incredibly cheap. BMY stock is worth at least 46% more than today, based on its historical yield, P/E ratios, and peer comparisons.

Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock

Bayer AG

Biogen

Bank of New York Mellon

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Altria

Merck

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Opdivo Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial.....

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial

The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.

bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.

FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

bluebird bio

The CAR T cell therapy treatment Bristol Myers and Bluebird Bio are developing to treat the blood cancer multiple myeloma got FDA priority review, after earlier rejection; BLUE stock popped.
The post Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority Review appeared first on Investor's Business Daily.

Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority Review

News for Bristol-Myers Stock (BMY)